Elsevier

Vaccine

Volume 14, Issues 17–18, December 1996, Pages 1677-1685
Vaccine

Paper
Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres

https://doi.org/10.1016/S0264-410X(96)00149-1Get rights and content

Abstract

Induction of systemic and mucosal immune responses following oral administration of biodegradable poly(d,l-lactic acid) (PDLLA) microspheres containing a model antigen, ovalbumin (OVA) was studied using microspheres with different average diameters of 0.6, 1.0, 4.0, 7.0, 11.0, 15.0, 21.0, and 26.0 μm. They were prepared from double emulsion with the solvent evaporation method, followed by size fractionation on counterflow elutriation. OVA was released from the microspheres in vitro over 80 days, irrespective of their size. Production of the serum anti-OVA IgG antibody and secretory OVA-specific IgA antibody in the mice gut was assessed following the oral administration of PDLLA microspheres containing OVA. Microspheres with a diameter of 4.0 μm enhanced the serum antibody in contrast with that of free OVA, but were not effective in inducing the gut secretion of IgA antibody. On the other hand, OVA-containing microspheres with a diameter of 7.0 μm enhanced IgA secretion to a significant extent compared with free OVA, whereas those with 26.0 μm in diameter were ineffective. Body distribution study revealed that the amount of microspheres taken up into Peyer's patches (PP) increased with the increasing size up to 11.0 μm, thereafter decreased, and finally became zero when their diameters were 21.0 μm or larger. The microspheres taken up into PP were translocated to the spleen, but no microspheres were noticed in the spleen when the size was larger than 5 μm. After being taken up into PP, microspheres <5 μm in diameter seemed to be transported to the spleen, a systemic lymphoid tissue, where the released antigen stimulated a serum antibody response, but larger microspheres probably remained at PP without being tanslocated to the spleen over the course of their antigen release, leading to induction of IgA secretion. It was concluded that the body distribution pattern of microspheres following the PP uptake was a key factor to regulate the induction of systemic and mucosal immune responses.

References (37)

  • J.R. McGee et al.

    The mucosal immune system: from fundamental concepts to vaccine development

    Vaccine

    (1992)
  • D.T. O'Hagen et al.

    Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immnization

    Vaccine

    (1898)
  • D.T. O'Hagen et al.

    Microparticles as potentially orally active immunological adjuvants

    Vaccine

    (1989)
  • D.T. O'Hagen et al.

    Biodegradable microparticles as controlled release antigen delivery systems

    Immunology

    (1991)
  • Z. Moldoveanu et al.

    Oral immunization with influenza virus in biodegradable microspheres

    J. Infect. Dis.

    (1993)
  • D.T. O'Hagen et al.

    Controlled release microparticles for oral immunization

    Int. J. Pharm.

    (1994)
  • Y. Tabata et al.

    Macrophage phagocytosis of biodegradable microspheres composed of L-lactic/glycolic acid homo- and copolymers

    J. Biomed. Mater. Res.

    (1988)
  • Y. Tabata et al.

    Polyanhydride microspheres that display near-constant release of water-soluble model drug compounds

    Pharm. Res.

    (1993)
  • Cited by (178)

    • Development of a solid dosage platform for the oral delivery of bilayer vesicles

      2017, European Journal of Pharmaceutical Sciences
      Citation Excerpt :

      After freeze-drying within the capsules, the contents were rehydrated with 0.5 mL ultrapure water, vortexed and then analysed for vesicle size and charge. The vesicles from the capsules reduced in size to an average of 4 to 5 μm with the zeta potential remaining highly negative (Fig. 5) which is within the size range suitable for uptake by the Peyer's patches (Tabata and Ikada, 1988; Ebel, 1990; Eldridge et al., 1990; Tabata et al., 1996). Similarly, antigen loading within the vesicles was compared across all 3 dosage form platforms (liquid, freeze-dried capsules and ODT).

    • Development of a single-dose recombinant CAMP factor entrapping poly(lactide-co-glycolide) microspheres-based vaccine against Streptococcus agalactiae

      2017, Vaccine
      Citation Excerpt :

      Various studies have demonstrated that particle size greatly affects vaccine immunogenicity [38,41], although no clear conclusions have been drawn. Particles with a diameter <5 μm induced a stronger humoral systematic reaction than particles >5 μm [42]. Similarly, a recent report that the smaller PLGE MS (<10 μm) entrapped with staphylococcal enterotoxin B toxoid had better immunogenicity than larger particles (10–110 μm) [43].

    • Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines

      2016, Journal of Controlled Release
      Citation Excerpt :

      The type of DC to which the antigen is delivered may influence the skewing of the immune response, but this is outside the scope of this review [40]. A study using orally dosed biodegradable polylactic acid (PLA) microparticles ranging from 1 to 26 μm in diameter showed that the uptake of these particles into intestinal lymphoid structures referred to as Peyer's patches, increased with increasing particle size up to 11 μm, and decreased again hereafter [41]. Microspheres smaller than 5 μm were subsequently translocated via the lymphatic system from the Peyer's patches to the spleen, whereas larger particles remained in the Peyer's patches in the jejunum.

    View all citing articles on Scopus
    View full text